Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 7,069 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Breast Cancer, Breast Neoplasms Clear all

Conditions: Advanced HER2-positive Breast Cancer or Gastric Cancer
Interventions: LJM716, Trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Boston, Massachusetts • Chapel Hill, North Carolina • Philadelphia, Pennsylvania

Conditions: Breast Cancer, Fatigue
Interventions: FACIT-Fatigue 52-point questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: gene expression analysis, microarray analysis, polymorphism analysis, proteomic profiling, flow cytometry, immunologic technique, laboratory biomarker analysis, biopsy; Genetic · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Breast Carcinoma, Colorectal Adenocarcinoma, Bladder Carcinoma
Interventions: Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breastcancer, Breast Neoplasm
Interventions: SV-BR-1-GM, Cyclophosphamide, Interferon-alpha-2b; Biological · Drug
Lead sponsor: BriaCell Therapeutics Corporation; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Santa Rosa, California • Plantation, Florida • Wichita, Kansas + 2 more

Conditions: Breast Cancer
Interventions: FFDM Mammography, DBT Mammography; Device
Lead sponsor: Fujifilm Medical Systems USA, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York + 2 more

Conditions: Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer, ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Interventions: ganetespib; Drug
Lead sponsor: Synta Pharmaceuticals Corp.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 8
States / cities: Birmingham, Alabama • Altanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Breast Cancer
Interventions: protein analysis, protein expression analysis, proteomic profiling, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, liquid chromatography, mass spectrometry, fine-needle aspiration, needle biopsy, radiomammography; Genetic · Other · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer, Obesity
Interventions: dietary intervention; Dietary Supplement
Lead sponsor: Rockefeller University; Other
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Contrast-enhanced mammography, Iodinated Contrast Media (ICM); Device · Drug
Lead sponsor: Wendie Berg; Other
Eligibility: 30 Years to 75 Years · Female only
Enrollment: 615 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Cranberry Township, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Breast Cancer Prevention
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 54 Years · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Carcinoma, Intraductal, Noninfiltrating, DCIS, Ductal Carcinoma In Situ
Interventions: Chloroquine Standard Dose (500mg/week), Chloroquine Low Dose (250mg/week), Breast Biopsy; Drug · Procedure
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 4
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Breast Cancer
Interventions: Four Conversations; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Breast Cancer, Breast Cancer
Interventions: Pulsed Electric Field (PEF) System, Questionnaires, Tumor Ablation; Device · Behavioral · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HER2-negative Breast Cancer
Interventions: Precision Medicine, Physican Decision Making; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Solid Tumors and Lymphomas
Interventions: Alobresib, Exemestane, Fulvestrant; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fort Wayne, Indiana • Goshen, Indiana + 1 more

Conditions: Breast Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Sarcoma, Gynecologic Cancer
Interventions: Doxorubicin, Sildenafil; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Triple Negative Breast Cancer
Interventions: Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin, Cyclophosphamide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 17
States / cities: Concord, California • Los Angeles, California • St. Helena, California + 14 more

Conditions: Breast Cancer
Interventions: Pembrolizumab, Nab-Paclitaxel; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 654 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Chandler, Arizona • Los Angeles, California • Palo Alto, California + 25 more

Conditions: Breast Cancer
Interventions: metformin hydrochloride, placebo; Drug · Other
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years to 74 Years
Enrollment: 3,649 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 280
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Scottsdale, Arizona + 213 more

Conditions: Breast Cancer
Interventions: Device: smartphone; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer, Pain, Lymphedema
Interventions: The-Optimal-Lymph-Flow, Arm Precaution; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 89 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Dasatinib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Search by objective public record fields.

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment

Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant

Vaccine Response With NT-I7

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Acquisition of Breast Mammography Images

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease

A Pilot Study of Docosahexaenoic Acid (DHA) in Obese Menopausal Women

Screening Contrast-Enhanced Mammography as an Alternative to MRI

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

Study of the Efficacy of Chloroquine in the Treatment of Ductal Carcinoma in Situ (The PINC Trial)

Four Conversations RCT

Pulsed Electric Field Ablation for Metastatic Breast Cancer

Functional Precision Oncology for Metastatic Breast Cancer

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities

Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)

Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer